La vocation de Sanofi est d'accompagner celles et ceux confrontés à des difficultés de santé.
Entreprise biopharmaceutique mondiale spécialisée dans la santé humaine qui prévient les maladies avec ses vaccins et propose des traitements innovants. Elle accompagne tant ceux qui sont atteints de maladies rares, que les millions de personnes souffrant d'une maladie chronique.
Sanofi et ses plus de 100 000 collaborateurs dans 100 pays transforment l'innovation scientifique en solutions de santé partout dans le monde.
Sanofi, Empowering Life, donner toute sa force à la vie.
54 Rue la Boetie
Paris, Ile De France 75008
Phone: 33153774000
www.sanofi.com
… EpiPen and other autoinjectors like Sanofi SA’s SNY Auvi-Q … or worsen. In February, ARS Pharmaceuticals released topline results from its … requested the completion of a pharmacokinetic/pharmacodynamic study assessing repeat doses of …
On Thursday, Novavax Inc (NASDAQ: NVAX ) reported second-quarter 2024 sales of $415 million, compared to $424 million a year, missing the consensus of $458.6 million . Second quarter 2024 licensing, royalties, and other revenue include $391 million associated with the $500 million upfront payment received under the Sanofi SA (NASDAQ: SNY ) agreement. The COVID-19 vaccine maker reported EPS of $0.99, up from $0.58 a year ago, but it missed the consensus of $1.64 . Net income for the second quarter of 2024 was $162 million, compared to a net income of $58 million in the same period in 2023. Also Read: Full story available on Benzinga.com
Achieved total revenue of $415 million in the second quarter of 2024 and ended the period with $1.1 billion in Cash Filed with the U.S. FDA and EMA for authorization of updated 2024-2025 formula COVID-19 vaccine Received $570 million in upfront payment and equity investment from Sanofi;…
PARIS (dpa-AFX) - Recent findings from the GMMG-HD7 phase 3 study, which is a two-part, double-randomized trial conducted by the German-speaking Myeloma Multicenter Group, reveal that Sarclisa (is…
Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant Sarclisa (isatuximab) in combina…
BURLINGAME, CALIFORNIA, UNITED STATES, August 7, 2024 /EINPresswire.com/ -- A new study titled GLP-1 Receptor Agonist Market 2024, published by the Coherent Market Insights, offers information on regional and global markets that is expected to …
… , subject to European Union approval. Sanofi manufacturing and supply global head … pharma strategy also attracted investments from other international companies. US-based Eli Lilly … Daiichi-Sankyo and Switzerland’s Roche are making billion-euro investments …
French pharma major Sanofi revealed it plans to construct a new, state-of-the-art insulin production facility at its BioCampus in Frankfurt Hchst.
Multiple sclerosis (MS) is a demyelinating disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. BURLINGAME, CALIFORNIA, UNITED STATES, August 2, 2024 /EINPresswire.com/ -- Latest Report, titled “ …
